Effect of Intraperitoneal Administration of Low-Molecular-Weight Heparin on Plasma Tissue Factor Pathway Inhibitor Levels in CAPD Patients

• Published in: Nephron Vol. 91; no. 1; pp. 162 - 163
• Main Authors: Demirkan, Fatih, Akarsu, Mesut, Sifil, Aykut, Tutucu, Kutlay Naci
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.05.2002
• Subjects: Anticoagulants - administration & dosage; Anticoagulants - pharmacology; Enzyme-Linked Immunosorbent Assay; Factor Xa - metabolism; Female; Heparin, Low-Molecular-Weight - administration & dosage; Heparin, Low-Molecular-Weight - pharmacology; Humans; Injections, Intraperitoneal; Lipoproteins - blood; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Short Communication; Continuous ambulatory peritoneal dialysis; Intraperitoneal low-molecular-weight heparin; Tissue factor pathway inhibitor
• ISSN: 1660-8151; 2235-3186
• DOI: 10.1159/000057620

We investigated the systemic effect of intraperitoneal low-molecular-weight heparin (LMWH) in continuous ambulatory peritoneal dialysis (CAPD) patients by measuring plasma total tissue factor pathway inhibitor (TFPI) levels, regarding the fact that the levels of plasma TFPI increases 2- to 4-fold after subcutaneous and intravenous administration of unfractioned heparin or LMWH. Eleven men and 6 women who had been on CAPD for 32 ± 26 months and 15 healthy controls were included in the study. After administration of intraperitoneal enoksiparin in dialysate, plasma samples were obtained 4 h later. TFPI levels were significantly higher in CAPD patients (207.8 ± 55 ng/ml) compared to the healthy subjects (72.5 ± 29 ng/ml) (p < 0.0001). Both TFPI levels (225.9 ± 47 vs. 207.8 ± 55 ng/ml) (p < 0.54) and plasma factor Xa (anti-FXa assay) (0.097 ± 0.14 vs. 0.093 ± 0.16 U/ml) (p < 0.54) levels did not show any statistical difference before and after intraperitoneal administration of LMWH. By these findings we might suggest that intraperitoneal LMWH does not have any systemic effect.